Update on therapeutic neovascularization - PubMed (original) (raw)
Review
Update on therapeutic neovascularization
Yihai Cao et al. Cardiovasc Res. 2005.
Abstract
Therapeutic neovascularization for cardiovascular ischemia is a promising avenue in spite of disappointing early clinical trial results. The concept of three different mechanisms of neovascularization has served to define potential therapeutic targets such as vascular remodeling and stem cell recruitment, but it is anticipated that this will lose significance as the pleiotropic nature of angiogenic cytokines becomes fully understood. With the rapidly growing body of data on growth factors and pro-angiogenic strategies, approaches will emerge that are more effective than the ones that have been tested clinically thus far. Combinations of growth factors, for instance to stabilize vessels, or growth factors combined with cell transplants deserve more attention but will make the design of preclinical and clinical studies increasingly complex. Recent developments suggest that when using the appropriate dose and treatment regimens, even single growth factor therapy can result in stable and functional vessels. Whether gene therapy or protein therapy will be optimal for this purpose depends mainly on technical developments in vector design and production and on progress in the engineering of slow release matrix formulations for proteins. With the increasing complexity of therapeutic strategies, it remains imperative that these approaches are rationally based on fundamental and preclinical data.
Similar articles
- The rational phase of therapeutic angiogenesis.
Post MJ, Simons M. Post MJ, et al. Minerva Cardioangiol. 2003 Oct;51(5):421-32. Minerva Cardioangiol. 2003. PMID: 14551513 Review. - [Angiogenesis and vasculogenesis. Therapeutic strategies for stimulation of postnatal neovascularization].
Kalka C, Asahara T, Krone W, Isner JM. Kalka C, et al. Herz. 2000 Sep;25(6):611-22. doi: 10.1007/pl00001974. Herz. 2000. PMID: 11076319 Review. German. - Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation.
van Weel V, van Tongeren RB, van Hinsbergh VW, van Bockel JH, Quax PH. van Weel V, et al. Ann Vasc Surg. 2008 Jul-Aug;22(4):582-97. doi: 10.1016/j.avsg.2008.02.017. Epub 2008 May 27. Ann Vasc Surg. 2008. PMID: 18504100 Review. - Angiogenic Growth Factors for Coronary Artery Disease: Current Status and Prospects.
Guo M, Shi JH, Wang PL, Shi DZ. Guo M, et al. J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):130-141. doi: 10.1177/1074248417735399. Epub 2017 Oct 12. J Cardiovasc Pharmacol Ther. 2018. PMID: 29025278 Review. - Therapeutic neovascularization for peripheral arterial diseases: advances and perspectives.
Zhou B, Poon MC, Pu WT, Han ZC. Zhou B, et al. Histol Histopathol. 2007 Jun;22(6):677-86. doi: 10.14670/HH-22.677. Histol Histopathol. 2007. PMID: 17357097 Review.
Cited by
- Combinatorial Treatment with Apelin-13 Enhances the Therapeutic Efficacy of a Preconditioned Cell-Based Therapy for Peripheral Ischemia.
Samura M, Morikage N, Suehiro K, Tanaka Y, Nakamura T, Nishimoto A, Ueno K, Hosoyama T, Hamano K. Samura M, et al. Sci Rep. 2016 Jan 14;6:19379. doi: 10.1038/srep19379. Sci Rep. 2016. PMID: 26763337 Free PMC article. - Tumour vascularization: sprouting angiogenesis and beyond.
Hillen F, Griffioen AW. Hillen F, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502. doi: 10.1007/s10555-007-9094-7. Cancer Metastasis Rev. 2007. PMID: 17717633 Free PMC article. Review. - Single Nucleotide Polymorphism in Patients with Moyamoya Disease.
Park YS. Park YS. J Korean Neurosurg Soc. 2015 Jun;57(6):422-7. doi: 10.3340/jkns.2015.57.6.422. Epub 2015 Jun 30. J Korean Neurosurg Soc. 2015. PMID: 26180609 Free PMC article. Review. - Engineering dextran-based scaffolds for drug delivery and tissue repair.
Sun G, Mao JJ. Sun G, et al. Nanomedicine (Lond). 2012 Nov;7(11):1771-84. doi: 10.2217/nnm.12.149. Nanomedicine (Lond). 2012. PMID: 23210716 Free PMC article. Review. - Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species.
Sun D, McCrae KR. Sun D, et al. Blood. 2006 Jun 15;107(12):4714-20. doi: 10.1182/blood-2005-09-3584. Epub 2006 Jan 17. Blood. 2006. PMID: 16418331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources